The efficacy and safety of activated vitamin D for CKD-MBD

Nobuki Hayakawa, Atsushi Suzuki

Research output: Contribution to journalArticle

Abstract

Metabolic bone disorders that are represented by secondary hyperparathyroidism occur with the progression of chronic kidney disease(CKD). The administration of activated vitamin D is expected to improve high-turnover bone disorders and is widely used for the management of bone mineral diseases in patients with CKD and end-stage renal disease. CKD is an underlying disease of secondary osteoporosis and coexists with primary osteoporosis at a high rate. With regard to osteoporosis patients with renal insufficiency, the administration of activated vitamin D is also thought to reduce the fracture incidence by both increasing bone mass and reducing falls.

Original languageEnglish
Pages (from-to)1333-1338
Number of pages6
JournalClinical calcium
Volume26
Issue number9
Publication statusPublished - 01-09-2016

Fingerprint

Chronic Renal Insufficiency
Vitamin D
Osteoporosis
Safety
Bone and Bones
Secondary Hyperparathyroidism
Bone Remodeling
Bone Diseases
Chronic Kidney Failure
Renal Insufficiency
Minerals
Incidence

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Hayakawa, Nobuki ; Suzuki, Atsushi. / The efficacy and safety of activated vitamin D for CKD-MBD. In: Clinical calcium. 2016 ; Vol. 26, No. 9. pp. 1333-1338.
@article{03be9e4eb07d4a0b97b0882299fe606d,
title = "The efficacy and safety of activated vitamin D for CKD-MBD",
abstract = "Metabolic bone disorders that are represented by secondary hyperparathyroidism occur with the progression of chronic kidney disease(CKD). The administration of activated vitamin D is expected to improve high-turnover bone disorders and is widely used for the management of bone mineral diseases in patients with CKD and end-stage renal disease. CKD is an underlying disease of secondary osteoporosis and coexists with primary osteoporosis at a high rate. With regard to osteoporosis patients with renal insufficiency, the administration of activated vitamin D is also thought to reduce the fracture incidence by both increasing bone mass and reducing falls.",
author = "Nobuki Hayakawa and Atsushi Suzuki",
year = "2016",
month = "9",
day = "1",
language = "English",
volume = "26",
pages = "1333--1338",
journal = "Clinical calcium",
issn = "0917-5857",
publisher = "Iyaku (Medicine & Drug) Journal Co",
number = "9",

}

The efficacy and safety of activated vitamin D for CKD-MBD. / Hayakawa, Nobuki; Suzuki, Atsushi.

In: Clinical calcium, Vol. 26, No. 9, 01.09.2016, p. 1333-1338.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The efficacy and safety of activated vitamin D for CKD-MBD

AU - Hayakawa, Nobuki

AU - Suzuki, Atsushi

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Metabolic bone disorders that are represented by secondary hyperparathyroidism occur with the progression of chronic kidney disease(CKD). The administration of activated vitamin D is expected to improve high-turnover bone disorders and is widely used for the management of bone mineral diseases in patients with CKD and end-stage renal disease. CKD is an underlying disease of secondary osteoporosis and coexists with primary osteoporosis at a high rate. With regard to osteoporosis patients with renal insufficiency, the administration of activated vitamin D is also thought to reduce the fracture incidence by both increasing bone mass and reducing falls.

AB - Metabolic bone disorders that are represented by secondary hyperparathyroidism occur with the progression of chronic kidney disease(CKD). The administration of activated vitamin D is expected to improve high-turnover bone disorders and is widely used for the management of bone mineral diseases in patients with CKD and end-stage renal disease. CKD is an underlying disease of secondary osteoporosis and coexists with primary osteoporosis at a high rate. With regard to osteoporosis patients with renal insufficiency, the administration of activated vitamin D is also thought to reduce the fracture incidence by both increasing bone mass and reducing falls.

UR - http://www.scopus.com/inward/record.url?scp=85021848668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021848668&partnerID=8YFLogxK

M3 - Article

C2 - 27561349

AN - SCOPUS:85021848668

VL - 26

SP - 1333

EP - 1338

JO - Clinical calcium

JF - Clinical calcium

SN - 0917-5857

IS - 9

ER -